Search | Clinical Trials Finder

Conditions: Depression
Interventions: Org 24448, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 21 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Bethesda, Maryland • New York, New York

Conditions: Alzheimer Disease, Dementia
Interventions: tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS., tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver sham tDCS.; Device
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Schizophrenia, Impulsive Behavior
Interventions: Nicotine Patch, 7 Mg/24 Hr, Placebo patch; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acne
Interventions: Skin Nutraceutical Supplement, Placebo pill; Dietary Supplement · Other
Lead sponsor: Nutraceutical Wellness Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Rabies, Rabies Immunisation
Interventions: ChAd155-RG, Placebo, Rabies Vaccine; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Hypoactive Sexual Desire Disorder, Sexual Dysfunctions, Psychological
Interventions: Ginkgo Biloba, Sex Therapy (genital focus); Drug · Behavioral
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Covid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress Syndrome
Interventions: MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8); Drug
Lead sponsor: AVEM HealthCare; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Panorama City, California

Conditions: Alcohol Withdrawal
Interventions: Prazosin, 12-Step Facilitation with Relapse Prevention and Contingency Management; Drug · Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: COVID-19, SARS-CoV2
Interventions: SAB-185, Normal saline; Biological · Other
Lead sponsor: SAb Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 3
States / cities: Wichita, Kansas • Syracuse, New York • San Antonio, Texas

Conditions: fMRI, Alcohol Drinking, Alcoholism
Interventions: Ghrelin, Placebo, fMRI, Alcohol; Drug · Procedure
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone; Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 8
States / cities: Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more

Conditions: Pain
Interventions: Ethyl Chloride Topical Aerosol Anesthetic, Nature's Tears Sterile Water; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Covid19
Interventions: Famotidine 20 milligram tablet; Drug
Lead sponsor: drpykessupplements.com; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Fairfield, Connecticut

Conditions: Systemic Lupus Erythematosus, Arthritis
Interventions: mycophenolate mofetil, placebo; Drug · Other
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 14 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions: Trilaciclib, Placebo, Gemcitabine, Carboplatin; Drug
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more

Conditions: Psoriasis (PsO), Psoriatic Arthritis (PsA)
Interventions: Aspirin, Clopidogrel, Placebo; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases, Cardiovascular Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Interventions: Pulmonary Artery Denervation (PADN), Sham procedure control; Device
Lead sponsor: Pulnovo Medical, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 6
States / cities: Tucson, Arizona • Houma, Louisiana • Detroit, Michigan + 3 more

Conditions: Diabetes Mellitus, Type 1, Diabetes, Diabetes, Autoimmune
Interventions: ILT-101 (Aldesleukin; IL-2), Treatment-Placebo Arm, Placebo Arm; Biological · Other
Lead sponsor: Jay S. Skyler; Other
Eligibility: 8 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Age-Related Macular Degeneration
Interventions: Active Comparator CT1812, Placebo Comparator; Drug
Lead sponsor: Cognition Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 19
States / cities: Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 15 more

Conditions: Children, Lacerations, Procedures, Child, Pain
Interventions: hydrocodone/acetaminophen, Sugar water; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 2 Years to 17 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: ELLIPTA placebo DPI, DISKUS placebo DPI, HandiHaler placebo DPI, Inhaler preference questionnaires; Device · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 18
States / cities: Orlando, Florida • Natchitoches, Louisiana • Saint Charles, Missouri + 14 more

Conditions: Onychomycosis
Interventions: Laser Treatment (Pulsed Nd:YAG 1064 nm Laser); Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Orthostatic Hypotension, Pure Autonomic Failure, Multiple System Atrophy, Autonomic Failure
Interventions: Abdominal compression, Sham abdominal compression, Placebo pill, midodrine; Other · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Paroxysmal Atrial Fibrillation, Indications for CABG
Interventions: botulinum toxin injection, 0.9% normal saline injection, Implantable loop recorder; Biological · Device
Lead sponsor: Meshalkin Research Institute of Pathology of Circulation; Network
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Org 24448 to Treat Major Depression

Neurostimulation for Cognitive Enhancement in Alzheimer's Disease

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

RCT of an Oral Acne Supplement for Adult Women

Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects

Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction

The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19

Prazosin for Alcohol Use Disorder With Withdrawal Symptoms

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Skin Refrigerant to Reduce the Pain Associated With IV Insertion

Remotely-conducted Trial of Famotidine vs Placebo for Patients at Home With Coronavirus (COVID) of 2019 (COVID-19)

Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

A Clinical Trial of Antiplatelets in Psoriasis

A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

Low-dose IL-2 in Established T1D - The "PROREG" Study

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Pain and Anxiety Management With Oral Narcotic for Pediatric Suture Repair

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser

Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery